UCB will pay $650m upfront and up to $500m in future milestones.
Modern technology could help lower barriers to developing therapies for rare diseases, writes Dr. Rowland Illing, chief ...
Belgium's UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona Therapeutics and ...